

RENISHAW Diagnostics

January 2009

New cleaning verification test - Rapid analysis with SERS dramatically cuts production downtime

Glasgow, 28 Jan 2009: D3 Technologies Ltd, a world leading provider of trace level detection technology, are developing a new cleaning verification procedure which cuts swab and rinse analysis time from days to hours, significantly reducing production downtime.

The test utilizes D3's patented Klarite™ substrate technology and Surface-Enhanced Raman Spectroscopy (SERS) know-how to provide a powerful new analytical tool to the pharmaceutical industry. It is a simple, easy to adopt procedure which provides highly reproducible results.

Klarite™ is capable of detecting trace quantities of analytes down to parts per billion levels. In addition, all components in an analytical mixture can be detected simultaneously, overcoming the need to 'search' for contaminants. A robust calibration curve can be generated so that known analytes can be readily quantified.

Cleaning verification is an important consideration in pharmaceutical production. Stringent cleaning protocols are essential, both for regulatory compliance and contamination control.

For further details please contact D3 Technologies on +44 (0)141 577 7900 or at info@d3technologies.co.uk

New partnership to develop advanced pan-fungal diagnostic assay

Cardiff & Glasgow, 21 January 2009: D3 Technologies Ltd, a world leading provider of novel detection technologies, and the research team in the Department of Medical Microbiology, School of Medicine Cardiff University, in association with the National Public Health Service for Wales, have signed an agreement to develop an advanced multiplex pan-fungal diagnostic assay.

Traditional laboratory tests can take up to 48 hours to provide a diagnostic result, during which time the patient may be at high risk. The ability to give clinicians a clear indication of the presence or absence of infection within 8 hours is expected to markedly improve treatment success. Moreover, the aim to identify the fungal type at speciate level will allow a more tailored therapeutic regimen to be employed.

A pan-European clinical evaluation of the assay is planned to commence in December 2009.
For further details please contact D3 Technologies on +44 (0)141 577 7900 or at info@d3technologies.co.uk